DOI QR코드

DOI QR Code

Cancer Preventive Effects of Whole Cell Type Immunization against Mice Ehrlich Tumors

  • Aysan, Erhan (Department of General Surgery, Bezmialem Vakif University) ;
  • Bayrak, Omer Faruk (Department of Genetics and Bioengineering, Yeditepe University) ;
  • Aydemir, Esra (Department of Genetics and Bioengineering, Yeditepe University) ;
  • Telci, Dilek (Department of Genetics and Bioengineering, Yeditepe University) ;
  • Sahin, Fikrettin (Department of Genetics and Bioengineering, Yeditepe University) ;
  • Yardimci, Cem (Department of Microbiology, Istanbul Educational and Research Hospital) ;
  • Muslumanoglu, Mahmut (Department of General Surgery, Bezmialem Vakif University)
  • Published : 2013.06.30

Abstract

Background: Effects of whole cell type immunization on mice Ehrlich tumours were evaluated. Materials and Methods: After preliminary study, mice were divided two major groups; $1{\times}1000$ and $100{\times}1000$ live Ehrlich cell transferred major groups, each divided into four subgroups (n: 10). Study groups were immunized with Ehrlich cell lysates in 0, 3, 7, $14^{th}$ days and after 30 days of last immunization, live Ehrlich cells were transferred. Mice were observed for six months and evaluated for total and cancer free days. Results: Out of $100{\times}1000$ cell transferred solid type study group, all study group mean and tumour free periods were statistically longer than control groups. All $1{\times}1000$ Ehrlich cell transferred study groups survived significantly longer than $100{\times}1000$ Ehrlich cell transferred groups. Conclusions: Ehrlich mice tumours were prevented and survival prolonged with whole cell type immunization. Effects are related to the number of transferred tumor cells.

Keywords

Cancer;prevention;whole cell immunization;Ehrlich cell tumours

References

  1. Niang M, Soukup T, Zivny P, et al (2011). Biochemical and pharmacological effects of mitoxantrone and acetyl-lcarnitine in mice with a solid form of ehrlich tumour. Chemotherapy, 57, 35-42. https://doi.org/10.1159/000321296
  2. Niu H, Dong Z, Dong F (2004). Experimental and clinical research of dendritic cell and syngeneic immunotherapy of brain glioma. Chin-Ger J Clin Oncol, 3, 147-50.
  3. Oka Y, Tsuboi A, Taguchi T, et al (2004). Induction of WT1 (Wilms' tumor gene)spcific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. PNAS, 101, 13885-90. https://doi.org/10.1073/pnas.0405884101
  4. Pardoll DM (2000). Therapeutic vaccination for cancer. Clin Immunol, 95, 44-62. https://doi.org/10.1006/clim.1999.4819
  5. Pessina A, Brambilla P, Mocarelli P (1980). Surface antigen on Ehrlich ascites tumor cells. Biomedicine, 33, 105-9.
  6. Reang P, Gupta M, Kohli K (2006). Biological response modifiers in cancer. Med Gen Med, 8, 33-6. https://doi.org/10.1097/01.gim.0000195894.67756.8b
  7. Rinaldi M, Fioretti D, Iurescia S, et al (2008). Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model. Biocehm Biophysic Res Comm, 370, 279-84. https://doi.org/10.1016/j.bbrc.2008.03.076
  8. Salem FS, Badr MO, Neamat-Allah AN (2011). Biochemical and pathological studies on the effects of levamisole and chlorambucil on Ehrlich ascites carcinoma-bearing mice. Vet Ital, 47, 89-95.
  9. Sauter B, Albert ML, Francisco L, et al (2000). Consequences of cell death : exposure to necrotic tumour cells but not primary tissue cells or apoptotic cells or apoptotic cells induces the maturation of immunostimulatory dendritic cells. J Exp Med, 191, 423-34. https://doi.org/10.1084/jem.191.3.423
  10. Small EJ, Sacks N, Nemunaitis J, et al (2007). Granulocyte macrophage colony stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res, 13, 3883-91. https://doi.org/10.1158/1078-0432.CCR-06-2937
  11. Suckow MA, Wolter WR, Pollard M (2005). Prevention of de novo prostate cancer by immunization with tumor-derived vaccines. Cancer Immunol Immunother, 54, 571-6. https://doi.org/10.1007/s00262-004-0612-y
  12. Zeng J, Cai S, Yi Y, et al (2009). Prevetion of spontaneous tumor development in a ret transgenic mice model by ret peptide vaccination with Indoleamine 2,3-dioxygenase inhibitor 1-methyl trypophan. Cancer Res, 69, 3963-70. https://doi.org/10.1158/0008-5472.CAN-08-2476
  13. Zhu J, Shi H, Zhang H (2000). Photodynamic therapy of malignancy of skin with a He-Ne laser. Chin J Lasers, 27, 95-6.
  14. De Gruijl TD, van den Eertwegh AJ, Pinedo HM, et al (2008). Whole-cell cancer vaccination: from autologous to allogeneic tumorand dendritic cell-based vaccines. Cancer Immunol Immunother, 57, 1569-77. https://doi.org/10.1007/s00262-008-0536-z
  15. Ehrlich P, Apolant H (1905). Beobachtungen uber maligne mausentumoren. Berlin Klin Wochenschr, 42, 871-4.
  16. Fernandez A, Mondai S, Heidelberger C (1980). Probabilistic view of the transformation of cultured C3H/10'/2 mouse embryo fibroblasts by 3-methylcholanthrene. Proc Nati Acad Sci, 77, 7272-6. https://doi.org/10.1073/pnas.77.12.7272
  17. Frieden TR, Myers JE, Krauskopf MS, et al (2008). A public health approach to winning the war against cancer. Oncologist, 13, 1306-13. https://doi.org/10.1634/theoncologist.2008-0157
  18. Hana MG, Brandhorst JS, Peters LC (1979). Active specific immunotherapy of residual micrometastases: an evaluation of sources, doss and ratios of BCG with tumour cells. Cancer Immunol Immunther, 7, 165-73.
  19. Hanna MG, Hoover HC, Vermorken JB, et al (2001). Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumour cell vaccine: first randomized phase III trials show promise. Vaccine, 19, 2576-82. https://doi.org/10.1016/S0264-410X(00)00485-0
  20. Iurescia S, Fioretti D, Pierimarchi P, et al (2010). Genetic immunization with CDR3-based fusion vaccine confers protection and long term tumor free survival in Mice model of lymphoma. J Biomed Biotechnol, 27, 1-9.
  21. Jaffee EM, Hruban RH, Biedrzycki B, et al (2001). Novel allogeneic granulocyte-macrophage colont stimulating factor-secreting tumour vaccine for pancreatic cancer; a phase I trial of safety and immune activation. J Clin Oncol, 19, 145-56.
  22. Jema A (2006). How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco smoking? Tob Control, 15, 345-7. https://doi.org/10.1136/tc.2006.017749
  23. Jocham D, Richter A, Hoffmann L, et al (2004). Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet, 363, 594-9. https://doi.org/10.1016/S0140-6736(04)15590-6
  24. Jukanti R, Devraj G, Shashank AS, et al (2011). Biodistribution of ascorbyl palmitate loaded doxorubicin pegylated liposomes in solid tumor bearing mice. J Microencapsul, 28, 142-9. https://doi.org/10.3109/02652048.2010.542496
  25. Liu BY, Chen XH, Gu QL, et al (2004). Antitumor effects of vaccine consisting of dendritic cells pulsed with tumor RNA from gastric cancer. Gastric Cancer, 10, 630-3.
  26. Mashanova OG, Romanov YA, Antohin AI, et al (2010). Relationship between proliferation of Ehrlich ascitic tumor cells and status of the chalone system under conditions of modified photoregimen. Bull Exp Biol Med, 149, 746-8. https://doi.org/10.1007/s10517-010-1042-9
  27. Michael A, Ball G, Quatan N, et al (2005). Delayed disease progression after allogeneic cell vaccination in hormoneresistant prostate cancer and correlation with immunologic variables. Clin Cancer Res, 11, 4469-78. https://doi.org/10.1158/1078-0432.CCR-04-2337
  28. Nagorsen D, Thiel E (2006). Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res. 12: 3064-3069. https://doi.org/10.1158/1078-0432.CCR-05-2788
  29. Baars A, Claessen AME, van den Eertwegh AJM, et al (2000). Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Ann Oncol, 11, 965-70. https://doi.org/10.1023/A:1008363601515
  30. Bailar JC, Gornik HL (2006). Cancer undefeated. N Engl J Med, 29, 1569-74.
  31. Banchereau J, Schuler-Thurner B, Palucka AK, et al (2001). Dendritic cells as vectors for therapy. Cell, 106, 271-4. https://doi.org/10.1016/S0092-8674(01)00448-2
  32. Banchereau J, Steinman RM (1998). Dendritic cells and the control of immunity. Nature, 392, 245-52. https://doi.org/10.1038/32588
  33. Berd D, Sato T, Maguire HC Jr, et al (2004). Immunopharmacologcal analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol, 22, 403-15.
  34. Bodey B, Bodey B Jr, Siegel SE, et al (2000). Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res, 20, 2665-76.
  35. Chen L, Watkins JF (1970). Evidence against the presence of H2 histocompatibility antigens in Ehrlich ascites tumour cells. Nature, 225, 734-5. https://doi.org/10.1038/225734a0

Cited by

  1. Impact of IL-2 and IL-2R SNPs on Proliferation and Tumor-killing Activity of Lymphokine-Activated Killer Cells from Healthy Chinese Blood Donors vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7965